Home » Topics » Conferences

Conferences
RSS

ACS news flash: Agouron investigates CDK inhibitors as anticancer agents

Aug. 27, 1999

Clinical candidate selected from 5-ht6 receptor antagonist program at Roche

Aug. 27, 1999

The aging heart: Should we refine management?

Aug. 27, 1999

P-SCN-Bz-HEHA, a bifunctional chelating agent designed to enable use of Ac-225 in radioimmunotherapy

Aug. 26, 1999

Highlights from ACS: integrin antagonist SC-72115 is a potent angiogenesis inhibitor in vivo

Aug. 26, 1999

Cytoskeleton employs novel HTS assay to identify new tubulin ligands

Aug. 26, 1999

Meiji Seika also shows interest in study of integrin receptor antagonists

Aug. 26, 1999

NMI-377, an NO-donating diclofenac derivative with decreased GI side effects

Aug. 26, 1999

Advances in the immunotherapy of cocaine abuse at Scripps Research Institute

Aug. 26, 1999

ACS presentation for new factor Xa inhibitor from Rhone-Poulenc Rorer

Aug. 25, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 29, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...